|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Einzig AI, Wiernik PH, Sasloff J, Runowicz
CD and Goldberg GL: Phase II study and long-term follow-up of
patients treated with Taxol for advanced ovarian adenocarcinoma. J
Clin Oncol. 10:1748–1753. 1992.PubMed/NCBI
|
|
3
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robinson DR, Wu YM and Lin SF: The protein
tyrosine kinase family of the human genome. Oncogene. 19:5548–5557.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohashi K, Mizuno K, Kuma K, Miyata T and
Nakamura T: Cloning of the cDNA for a novel receptor tyrosine
kinase, Sky, predominantly expressed in brain. Oncogene. 9:699–705.
1994.PubMed/NCBI
|
|
6
|
Sasaki T, Knyazev PG, Clout NJ, Cheburkin
Y, Göhring W, Ullrich A, Timpl R and Hohenester E: Structural basis
for Gas6-Axl signalling. EMBO J. 25:80–87. 2006. View Article : Google Scholar
|
|
7
|
Stitt TN, Conn G, Gore M, Lai C, Bruno J,
Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, et al: The
anticoagulation factor protein S and its relative, Gas6, are
ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
Cell. 80:661–670. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hafizi S and Dahlbäck B: Gas6 and protein
S: Vitamin K-dependent ligands for the Axl receptor tyrosine kinase
subfamily. FEBS J. 273:5231–5244. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wimmel A, Glitz D, Kraus A, Roeder J and
Schuermann M: Axl receptor tyrosine kinase expression in human lung
cancer cell lines correlates with cellular adhesion. Eur J Cancer.
37:2264–2274. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zwick E, Bange J and Ullrich A: Receptor
tyrosine kinase signalling as a target for cancer intervention
strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Meric F, Lee WP, Sahin A, Zhang H, Kung HJ
and Hung MC: Expression profile of tyrosine kinases in breast
cancer. Clin Cancer Res. 8:361–367. 2002.PubMed/NCBI
|
|
12
|
Craven RJ, Xu LH, Weiner TM, Fridell YW,
Dent GA, Srivastava S, Varnum B, Liu ET and Cance WG: Receptor
tyrosine kinases expressed in metastatic colon cancer. Int J
Cancer. 60:791–797. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo
SS, Lui WY and Lin WC: Clinical significance of AXL kinase family
in gastric cancer. Anticancer Res. 22B:1071–1078. 2002.
|
|
14
|
Challier C, Uphoff CC, Janssen JW and
Drexler HG: Differential expression of the ufo/axl oncogene in
human leukemia-lymphoma cell lines. Leukemia. 10:781–787.
1996.PubMed/NCBI
|
|
15
|
Tsou AP, Wu KM, Tsen TY, Chi CW, Chiu JH,
Lui WY, Hu CP, Chang C, Chou CK and Tsai SF: Parallel hybridization
analysis of multiple protein kinase genes: Identification of gene
expression patterns characteristic of human hepatocellular
carcinoma. Genomics. 50:331–340. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Györffy B and Lage H: A Web-based data
warehouse on gene expression in human malignant melanoma. J Invest
Dermatol. 127:394–399. 2007. View Article : Google Scholar
|
|
17
|
van Ginkel PR, Gee RL, Shearer RL,
Subramanian L, Walker TM, Albert DM, Meisner LF, Varnum BC and
Polans AS: Expression of the receptor tyrosine kinase Axl promotes
ocular melanoma cell survival. Cancer Res. 64:128–134. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Macleod K, Mullen P, Sewell J, Rabiasz G,
Lawrie S, Miller E, Smyth JF and Langdon SP: Altered ErbB receptor
signaling and gene expression in cisplatin-resistant ovarian
cancer. Cancer Res. 65:6789–6800. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rankin EB, Fuh KC, Taylor TE, Krieg AJ,
Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA and Giaccia AJ: AXL is
an essential factor and therapeutic target for metastatic ovarian
cancer. Cancer Res. 70:7570–7579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sainaghi PP, Castello L, Bergamasco L,
Galletti M, Bellosta P and Avanzi GC: Gas6 induces proliferation in
prostate carcinoma cell lines expressing the Axl receptor. J Cell
Physiol. 204:36–44. 2005. View Article : Google Scholar
|
|
21
|
Donato NJ: Imatinib is receptive to a
collaboration. Blood. 118:4009–4010. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gotlieb WH, Saumet J, Beauchamp MC, Gu J,
Lau S, Pollak MN and Bruchim I: In vitro metformin anti-neoplastic
activity in epithelial ovarian cancer. Gynecol Oncol. 110:246–250.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and
Xu GM: Metformin induces apoptosis of pancreatic cancer cells.
World J Gastroenterol. 14:7192–7198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Goodwin PJ, Pritchard KI, Ennis M, Clemons
M, Graham M and Fantus IG: Insulin-lowering effects of metformin in
women with early breast cancer. Clin Breast Cancer. 8:501–505.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hadad SM, Appleyard V and Thompson AM:
Therapeutic metformin/AMPK activation promotes the angiogenic
phenotype in the ERalpha negative MDA-MB-435 breast cancer model.
Breast Cancer Res Treat. 114:3912009. View Article : Google Scholar
|
|
27
|
Liu H, Scholz C, Zang C, Schefe JH, Habbel
P, Regierer AC, Schulz CO, Possinger K and Eucker J: Metformin and
the mTOR inhibitor everolimus (RAD001) sensitize breast cancer
cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Anticancer Res. 32:1627–1637. 2012.PubMed/NCBI
|
|
28
|
Nair V, Sreevalsan S, Basha R, Abdelrahim
M, Abudayyeh A, Rodrigues Hoffman A and Safe S: Mechanism of
metformin-dependent inhibition of mammalian target of rapamycin
(mTOR) and Ras activity in pancreatic cancer: Role of specificity
protein (Sp) transcription factors. J Biol Chem. 289:27692–27701.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Honjo S, Ajani JA, Scott AW, Chen Q,
Skinner HD, Stroehlein J, Johnson RL and Song S: Metformin
sensitizes chemotherapy by targeting cancer stem cells and the mTOR
pathway in esophageal cancer. Int J Oncol. 45:567–574.
2014.PubMed/NCBI
|
|
30
|
Ota S, Horigome K, Ishii T, Nakai M,
Hayashi K, Kawamura T, Kishino A, Taiji M and Kimura T: Metformin
suppresses glucose-6-phosphatase expression by a complex I
inhibition and AMPK activation-independent mechanism. Biochem
Biophys Res Commun. 388:311–316. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ben Sahra I, Regazzetti C, Robert G,
Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF,
Giorgetti-Peraldi S and Bost F: Metformin, independent of AMPK,
induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer
Res. 71:4366–4372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ming M, Sinnett-Smith J, Wang J, Soares
HP, Young SH, Eibl G and Rozengurt E: Dose-dependent AMPK-dependent
and independent mechanisms of berberine and metformin inhibition of
mTORC1, ERK, DNA synthesis and proliferation in pancreatic cancer
cells. PLoS One. 9:e1145732014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Linger RM, Keating AK, Earp HS and Graham
DK: TAM receptor tyrosine kinases: Biologic functions, signaling,
and potential therapeutic targeting in human cancer. Adv Cancer
Res. 100:35–83. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang KT, Tsai CM, Chiou YC, Chiu CH, Jeng
KS and Huang CY: IL-6 induces neuroendocrine dedifferentiation and
cell proliferation in non-small cell lung cancer cells. Am J
Physiol Lung Cell Mol Physiol. 289:L446–L453. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Block KM, Hanke NT, Maine EA and Baker AF:
IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell
lines. Pancreas. 41:773–781. 2012.PubMed/NCBI
|
|
36
|
Rodriguez LH and Johnson DE: Clinical
trial of cisplatinum (NSC 119875) in metastatic renal cell
carcinoma. Urology. 11:344–346. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Briscoe KE, Pasmantier MW, Ohnuma T and
Kennedy BJ: cis-Dichlorodiammineplatinum(II) and adriamycin
treatment of advanced ovarian cancer. Cancer Treat Rep.
62:2027–2030. 1978.PubMed/NCBI
|
|
38
|
Go RS and Adjei AA: Review of the
comparative pharmacology and clinical activity of cisplatin and
carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
|
|
39
|
Boeckman HJ, Trego KS and Turchi JJ:
Cisplatin sensitizes cancer cells to ionizing radiation via
inhibition of nonhomologous end joining. Mol Cancer Res. 3:277–285.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kohler DR and Goldspiel BR: Paclitaxel
(Taxol). Pharmacotherapy. 14:3–34. 1994.PubMed/NCBI
|
|
42
|
Stordal B, Pavlakis N and Davey R: A
systematic review of platinum and taxane resistance from bench to
clinic: An inverse relationship. Cancer Treat Rev. 33:688–703.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiralerspong S, Palla SL, Giordano SH,
Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi
GN and Gonzalez-Angulo AM: Metformin and pathologic complete
responses to neoadjuvant chemotherapy in diabetic patients with
breast cancer. J Clin Oncol. 27:3297–3302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lai SW, Chen PC, Liao KF, Muo CH, Lin CC
and Sung FC: Risk of hepatocellular carcinoma in diabetic patients
and risk reduction associated with anti-diabetic therapy: A
population-based cohort study. Am J Gastroenterol. 107:46–52. 2012.
View Article : Google Scholar
|
|
45
|
Garrett CR, Hassabo HM, Bhadkamkar NA, Wen
S, Baladandayuthapani V, Kee BK, Eng C and Hassan MM: Survival
advantage observed with the use of metformin in patients with type
II diabetes and colorectal cancer. Br J Cancer. 106:1374–1378.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sadeghi N, Abbruzzese JL, Yeung SC, Hassan
M and Li D: Metformin use is associated with better survival of
diabetic patients with pancreatic cancer. Clin Cancer Res.
18:2905–2912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bodmer M, Becker C, Meier C, Jick SS and
Meier CR: Use of metformin is not associated with a decreased risk
of colorectal cancer: A case-control analysis. Cancer Epidemiol
Biomarkers Prev. 21:280–286. 2012. View Article : Google Scholar
|
|
48
|
Bodmer M, Becker C, Jick SS and Meier CR:
Metformin does not alter the risk of lung cancer: A case-control
analysis. Lung Cancer. 78:133–137. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cossor FI, Adams-Campbell LL, Chlebowski
RT, Gunter MJ, Johnson K, Martell RE, McTiernan A, Simon MS, Rohan
T, Wallace RB, et al: Diabetes, metformin use, and colorectal
cancer survival in postmenopausal women. Cancer Epidemiol.
37:742–749. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Linger RM, Keating AK, Earp HS and Graham
DK: Taking aim at Mer and Axl receptor tyrosine kinases as novel
therapeutic targets in solid tumors. Expert Opin Ther Targets.
14:1073–1090. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee-Sherick AB, Eisenman KM, Sather S,
McGranahan A, Armistead PM, McGary CS, Hunsucker SA, Schlegel J,
Martinson H, Cannon C, et al: Aberrant Mer receptor tyrosine kinase
expression contributes to leukemogenesis in acute myeloid leukemia.
Oncogene. 32:5359–5368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin
W, Ke J, Huang J, Yeung SC and Zhang H: Metformin promotes
autophagy and apoptosis in esophageal squamous cell carcinoma by
downregulating Stat3 signaling. Cell Death Dis. 5:e10882014.
View Article : Google Scholar : PubMed/NCBI
|
